21 / 32
Role of liquid biopsy to select pts for
osimertinib
•
Always in pts not eligible for biopsy (bone metastases)
•
Liquid biopsy with highly sensitive methods, 70-80% sensitivity
Correlation of sensitivity with tumor burden
More reliable results if EGFR-activating mutation detected
If negative for T790M, tumor biopsy
•
Which is the optimal determination technique in plasma?